The increased understanding of such complex inflammatory pathways has resulted in the development of antibody-based biological therapies that target T2 cytokines such as IL-4, IL-5, and IL-13, which play key roles in the inflammatory processes underlying asthma [9]. This evidence concerns the gene IL4 and asthma.